BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15801952)

  • 21. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor leukocyte infusions in myeloid malignancies: new strategies.
    Porter DL; Antin JH
    Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.
    Laane E; Derolf AR; Björklund E; Mazur J; Everaus H; Söderhäll S; Björkholm M; Porwit-MacDonald A
    Haematologica; 2006 Jun; 91(6):833-6. PubMed ID: 16769587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The thorny issue of relapsed acute myeloid leukemia.
    Kubal T; Lancet JE
    Curr Opin Hematol; 2013 Mar; 20(2):100-6. PubMed ID: 23385612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
    Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haploidentical stem cell transplantation for children with acute leukaemia.
    Marks DI; Khattry N; Cummins M; Goulden N; Green A; Harvey J; Hunt LP; Keen L; Robinson SP; Steward CG; Cornish JM
    Br J Haematol; 2006 Jul; 134(2):196-201. PubMed ID: 16846478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
    Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
    Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin.
    Shenoy S; Smith FO
    Bone Marrow Transplant; 2008 Jan; 41(2):141-8. PubMed ID: 18176616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of acute myeloid leukemia: current approaches.
    Smits EL; Berneman ZN; Van Tendeloo VF
    Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.